A prospective comparative study of IMRT (using VMAT technique) versus 3DCRT with respect to toxicity and loco-regional response in locally advanced cervical carcinoma

Chittaranjan National Cancer Institute0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1) Histopathology confirmed primary carcinoma of cervix.
•2) Histopathology- squamous cell carcinoma.
•3) Intact and non-operated cervical carcinoma cases (wherever concurrent chemo-radiotherapy is
•indicated).
•4) FIGO stage IB3 to IIIB.
•5) Age 18 yrs â?? 70 years.
•6) No prior history of chemotherapy or pelvic radiotherapy.
•7) WHO performance status grade 0 to 2
•8) liver function test with in 2 times of upper normal level
•9) hematological parameters with in normal limit and kidney function test within normal limit
•10) Patients with no history or current clinical evidence of any Hematological or Bleeding
•11) HBsAG, Anti-HCV, HIV non-reactive patients.
•12) No history of drug use which results in Hematological toxicity.
•13) The patient who will understand and follow the instructions and must be able to participate in
•the study for the entire period.

•1) Age < 18 years and > 70 years.
•2) Patients with WHO performance status grade > 2.
•3) Post â?? op patients adviced to receive adjuvant radiotherapy.
•4) Stages IA1 â?? IB2 and stages IVA-IVB patients.
•5) Patients with pelvic and para-aortic nodal disease or who require extended field radiotherapy beyond the pelvis.
•6) Patients with deranged liver function test and kidney function test parameters.
•7) Severe, active co-morbidity, defined as follows:
•A. History of Unstable angina and/or congestive heart failure requiring hospitalization within the last 6months.
•B. History of myocardial infarction within the last 6 months.
•C. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration to the study.
•D. Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration.
•E. Clinical jaundice and/or history of bleeding disorder.
•8) Patients who have already received radiation to pelvis and prior history of chemotherapy.
•9) Patients not willing to take part in the study.

发起方